Abstract: Stimulation of glutamatergic tone has been causally linked to myocardial pathogenesis and amplified systemic blood pressure (BP). Memantine, a noncompetitive N-methyl-D-aspartate glutamatergic receptor (NMDA-R) antagonist, has been proposed to be an active cardioprotective drug. However, the efficacy of memantine and subsequently the possible involvement of the NMDA-R in the thyroxin (T4)-induced cardiovascular complications have never been investigated. We examined the effect of memantine (30 mg$kg 21 $d 21 ) on the T4 (500 mg$kg 21 $d 21 )-provoked increase in mouse BP, cardiac hypertrophy indicated by enlarged overall myocardial mass, and reformed reactions of the contractile myocardium both in vivo and ex vivo after 2 weeks of treatment. Memantine alone did not result in any cardiovascular pathology in mice. Instead, memantine significantly prevented the T4-triggered systemic hypertension. But, it did not reverse cardiac hypertrophy, coupled in vivo left ventricular dysfunction (LV) or ex vivo right ventricular (RV) papillary muscle contractile alterations of the T4-treated mice. Our results openly direct the cardiovascular safety and tolerability of memantine therapy. Yet, extra research is necessary to endorse these prospective advantageous outcomes. Also, we believe that this is the first study to inspect the possible role of NMDA-R in the T4-stimulated cardiovascular disorders and concluded that NMDA-R could play a key role in the T4-induced hypertension.
kept at the Research Animal Facility of The Ohio State University for the whole duration of the experimental procedures. The experimental procedures and protocols used in this study were approved by the Animal Care and Use Committee of the Ohio State University, conforming to the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health (National Institutes of Health publication No. 85-23, revised 1996).
Thyroxin (T4) and Memantine Hydrochloride Treatments
T4, sodium-L-thyroxin, from Sigma-Aldrich (St. Louis, MO) was prepared as previously described 27 and injected intraperitoneally at a dose of 500 mg$kg 21 $d 21 for 2 weeks as we reported before. [28] [29] [30] Memantine hydrochloride from SigmaAldrich was dissolved in normal saline and administered at a dose of 30 mg$kg 21 $d 21 by intraperitoneal injection before T4. Memantine dose was chosen based on a previous study showed that 30 mg$kg 21 $d 21 in mice constructs the 1 mM therapeutic steady-state plasma level as indicated by numerous preclinical and clinical studies. 31 Mice were divided into 4 groups based on treatment: vehicle (control group) (n = 16), memantine only (n = 14), T4 only (n = 17), and memantine + T4 (n = 15). At the end of the treatment period, mice underwent BP measurements, echocardiography, and electrocardiogram (ECG). Thereafter, mice were euthanized by cervical dislocation, and hearts were removed and processed for further experiments.
BP Measurements
BP was measured noninvasively in conscious untrained mice by the tail cuff method using a 6-Channel CODA High Throughput Acquisition system (Kent Scientific Corporation, Torrington, CT) as described before. 30 Each experimental session consisted of 10 acclimatization cycles followed by 10 BP measurement cycles. Only the accepted cycles as identified by the BP measurement software are included in the data analysis. The average of all accepted cycles from 1 session was used for systolic BP (SBP), diastolic BP (DBP), and mean arterial pressure (MAP) in each mouse.
Echocardiography
The in vivo LV dimension and contractile function in mice were evaluated by using a high-frequency ultrasound imaging system (VEVO 2100; Visual Sonics, Toronto, ON, Canada) as described before. [27] [28] [29] [30] Mice were anesthetized with isoflurane at a concentration of 3% and thereafter maintained at 1.5% isoflurane through nasal prongs during the whole procedure. The measurements were taken from the parasternal short-axis view in M-mode to view the LV movement during systole and diastole corresponding to the ECG. All data and imaging were analyzed by the Visual Sonics Cardiac Measurements Package.
ECG
ECG parameters including heart rate (HR), PR, QRS, and QT intervals were recorded noninvasively in fully conscious and unrestrained mice using the ECGenie system (Mouse Specifics, Inc, MA). Mice were placed onto the recording platform for sufficient time (about 30 minutes) to acclimate and trigger recordings when their paws are in contact with the recording electrodes. All data were then analyzed by e-MOUSE, a Physiological Data Analysis and Database Portal, as we previously reported. 28, 30 Heart Weight, Cardiac Muscle Preparation, and Experimental Setup First, mice were weighed, and 5 minutes after intraperitoneal heparin injection mice were euthanized by cervical dislocation. After bilateral thoracotomy, hearts were rapidly excised and placed in Krebs-Henseleit buffer containing (in mmol/L) 120 NaCl, 5 KCl, 2 MgSO 4 , 1.2 NaH 2 PO 4 , 20 NaH-CO 3 , 0.25 Ca 2+ , and 10 glucose, equilibrated with 95% O 2 -5% CO 2 , resulting in a pH of 7.4. In addition, 20 mmol/L 2,3-butanedione monoxime (BDM) was added to the dissection buffer to prevent cutting injury. [28] [29] [30] Extra noncardiac tissues, such as fat and pieces of lung, were carefully removed. After hearts were blotted gently on Kim wipes, they rapidly transferred to a small weigh dish that contained clean oxygenated Krebs-Henseleit/BDM buffer that was tarred to zero on an electronic analytical balance to get the exact wet heart weight (HW). HW/body weight (BW) ratios were then calculated and expressed as mg/g. Consequently, hearts were carefully opened, repeatedly perfused with the same oxygenated Krebs-Henseleit/ BDM buffer, and blood was thoroughly washed out. From the RV uniform linear papillary muscles were carefully dissected. The dimensions of muscles were measured using a calibration reticule in the ocular of the dissection microscope (40·, resolution ;10 mm). The cross-sectional areas were calculated assuming ellipsoid cross-sectional shapes. There was no significant difference between average dimensions (width · thickness · length) of the control (0.25 6 0.02 · 0. 16 With the use of the dissection microscope, muscles were mounted between basket-shaped extension of a force transducer (KG7; Scientific Instruments, Heidelberg, Germany) and a hook (valve end) connected to a micromanipulator as previously mentioned. [28] [29] [30] Muscles were superfused with the same buffer at 37.58C as above (with the exception that BDM was omitted) and stimulated at 4 Hz. Extracellular Ca 2+ concentration was raised to 2 mmol/L and muscles were allowed to stabilize for at least 30 minutes before the experimental protocol was initiated. The 4 Hz baseline was selected rather than a more physiological 12 Hz, as in our previous reports. [28] [29] [30] However, to study more physiological frequencies, 12 Hz contractions were also assessed, but only for brief periods. Generally, muscles were stretched to an optimal length, where a small increase in length resulted in nearly equal increases in resting tension and active developed tension. This length was selected to be comparable to the maximally attained length in vivo at the end of diastole. 32 To obtain a broad scope of quantitative data to dissect contractile function and dysfunction, 2 of the 3 main mechanisms used in vivo to physiologically modify force of contraction, frequency-dependent activation, and b-adrenergic stimulation were assessed in mouse papillary muscles under near physiological conditions as previously described. [28] [29] [30] This is because the third mechanism, which is the length-dependent activation (Frank-Starling mechanism), is well-sustained in the hearts of these T4-treated mice. 29 We assessed the effect of increasing stimulation frequencies between 4 and 14 Hz, spanning the entire in vivo range of the mouse. At each frequency, forces were allowed to reach steady state before data were recorded. The effects of b-adrenergic stimulation were also assessed by a concentration-response curve with isoproterenol (10 29 -10 26 mol/L) at a baseline stimulation frequency of 4 Hz.
In all experiments, performed peak isometric developed force (Fdev) was determined and normalized to the crosssectional area of the muscle. In addition, as a force-independent parameter of force decay kinetics, time to peak (TTP) force, and time from peak force to 50% relaxation (RT50) were determined. Muscles with an initial Fdev or a Fdev after restabilization after frequency-dependent activation ,5 mN/mm 2 were excluded from the analysis of all experimental parameters. In addition, muscles that displayed arrhythmia early at the initial isoproterenol concentrations were excluded from the final isoproterenol-Fdev data analysis. Furthermore, muscles that exhibited arrhythmia after the force-frequency assessment and before starting the isoproterenol experiments were not included either in the arrhythmia or in the final isoproterenol-Fdev data analysis (1 muscle from the control group and 1 from the T4 group).
Data Analysis and Statistics
Generally, a 2-tailed value of P # 0.05 was considered statistically significant. Data are presented as mean 6 SEM and were analyzed by either ordinary 1-way analysis of variance (ANOVA) or repeated measures ANOVA followed by Tukey-Kramer's post hoc multiple comparison test. Ordinary 1-way ANOVA assumes that the data are sampled from populations that follow Gaussian distributions. This assumption was tested using Kolmogorov and Smirnov test, which showed that all data sampled passed normality test. Also, it assumes that the data are sampled from populations with identical SDs, and this assumption was tested using Bartlett test. The cases, in which Bartlett test suggested significant differences among the SDs of the groups Kruskal-Wallis test (nonparametric ANOVA) was applied followed by Dunn's post hoc multiple comparison test.
However, ordinary repeated measures ANOVA assumes effective matching among means. If the matching seems not to be effective, Friedman test (nonparametric repeated measures AN-OVA) was applied followed by Dunn's post hoc multiple comparison test.
RESULTS
First, we did not observe a significant difference in the SBP (113.90 6 3.96 mm Hg), DBP (85.84 6 4.30 mm Hg), and MAP (94.83 6 4.14 mm Hg) of the mice treated only with memantine compared with the control (118.40 6 2.23 mm Hg), (94.24 6 2.23 mm Hg), and (101.91 6 2.20 mm Hg), respectively (Figs. 1A-C). Conversely, the T4 treatment as expected [17] [18] [19] [28] [29] [30] significantly increased the SBP (141.77 6 3.05 mm Hg; P , 0.001), DBP (112.11 6 3.06; mm Hg P , 0.001), and MAP (121.72 6 3.05 mm Hg; P , 0.001) compared with both the control and the memantine only-treated mice (Figs. 1A-C). Notably, concomitant administration of memantine with T4 significantly reduced the remarkably amplified SBP, DBP, and MAP after T4 treatment to a level that was not significant compared with both the control and the memantine only-treated mice (119.79 6 3.17 mm Hg; P , 0.001), (87.77 6 3.27 mm Hg; P , 0.001), and (98.15 6 3.20 mm Hg; P , 0.001), respectively (Figs. 1A-C).
Echocardiography analysis illustrated that memantine treatment could not cause a significant change in the LV ejection fraction (EF) (66.23 6 0.68%) ( Fig. 2A) or the fractional shortening (FS) (36.07 6 0.50%) (Fig. 2B ) compared with those of the control (EF: 67.59 6 0.87% and FS: 37.23 6 0.64%). However, in agreement with our former outcomes [28] [29] [30] and with others' data, 13,14 the T4 treatment led to LV systolic dysfunction as revealed by significantly decreased EF (58.79 6 1.40%) ( Fig. 2A) and FS (30.99 6 0.96%) (Fig.  2B ) compared with those of both the control (EF: P , 0.001 and FS: P , 0.001) and the memantine only-treated mice (EF: P , 0.01 and FS: P , 0.01). Also, concomitant administration of memantine with T4 could not inhibit the T4-prompted reduction in either the EF or the FS, and they were still significantly lower than those of the control (EF: 60.63 6 1.32%; P , 0.01 and FS: 32.31 6 0.93%; P , 0.01) (Figs. 2A, B) . Furthermore, echocardiographic assessment demonstrated that mice with memantine alone had no significant changes in the LV mass (108.69 6 4.01 mg) (Fig. 2C ) or FIGURE 1. BP measurements of mice. A, SBP; (B) DBP; (C) MAP. Control; n = 16, memantine; n = 14, T4; n = 17, and memantine + T4; n = 15. #Indicates a significant change compared with the T4 group; +indicates a significant change compared with both the control and the memantine groups. One-way ANOVA followed by Tukey-Kramer's post hoc multiple comparison test.
the LV mass/BW ratio (3.75 6 0.12 mg/g) (Fig. 2D ) compared with those of the control (LV mass: 106.24 6 3.40 mg and LV mass/BW: 3.63 6 0.09 mg/g). Nevertheless, the T4 treatment as we reported before [28] [29] [30] resulted in a marked increase in the LV mass (157.37 6 5.82 mg; P , 0.001) (Fig. 2C) and LV mass/ BW ratio (5.09 6 0.14 mg/g; P , 0.001) (Fig. 2D ) compared with those of both the control and the memantine only-treated mice. Memantine along with T4 treatment could not significantly diminish such T4-accelerated increases in LV mass or LV mass/BW ratio and they were still significantly higher than those of the control and the memantine only-treaded mice (148.09 6 5.15 mg; P , 0.001 and 5.18 6 0.17 mg/g; P , 0.001, respectively) (Figs. 2C, D) . However, the ECG analysis showed no significant difference in any of the parameters that were measured (HR, PR, QRS, and QT) among all groups, including the T4-treated mice as we formerly defined 28, 30 (Table 1) .
Evaluation of the BW using the Kruskal-Wallis test showed a P value of 0.0408, which is considered significant. However, the Dunn's multiple comparison test demonstrated a nonsignificant difference among the groups: control (29.53 6 0.30 g), memantine (28.92 6 0.39 g), T4 (30.88 6 0.59), and memantine + T4 (28.74 6 0.63 g). Yet, there was a quite nonsignificant difference in the BW of the memantine (P = 0.0815) and the memantine + T4 (P = 0.0968) compared with the T4-treated mice (Fig. 3A) . Besides, there was no significant difference in the HW (136.69 6 2.42 mg) or the HW/BW ratio (4.73 6 0.05 mg/g) of the mice treated with memantine alone compared with those of the control mice (HW: 139.13 6 2.10 mg and HW/BW: 4.71 6 0.06 mg/g) (Fig. 3B) . Alternatively, T4 treatment significantly increased both HW (186.83 6 3.71 mg: P , 0.001) and HW/BW ratio (6.06 6 0.09: P , 0.001) compared with both the control and the memantine only-treated mice (Fig. 3C) , which confirms the development of cardiac hypertrophy in harmony with our previous reports. [28] [29] [30] Memantine administration along with T4 treatment did not significantly decrease the T4-evoked increase in HW or HW/BW ratio and were still notably higher than those of the control and memantine only-treated mice (HW: 183.34 6 5.30 mg; P , 0.001 and HW/BW: 6.40 6 0.20 mg/g; P , 0.001) (Figs. 3B, C) . Finally, under proximate physiological temperature and at a preload leading to sarcomere length around the in vivo enddiastolic values of 2.2 mm, 32 the ex vivo experiments exemplified that there is no significant difference in the Fdev of the RV papillary muscles among the groups (P = 0.4684) at a stimulation frequency of 4 Hz, including the T4 group resembling our earlier records [28] [29] [30] [31] [32] : control: 26.0 6 3.7 mN/mm 2 , memantine: 22.6 6 4.6 mN/mm 2 , T4: 19.6 6 1.9 mN/mm 2 , and memantine + T4: 17.2 6 3.0 mN/mm 2 (Fig. 4A) . Moreover, muscles from the control and the memantine only-treated mice exhibited similar contractile profile as indicated by comparable TTP (47.1 6 1.2 vs. 46.3 6 1.7 ms) (Fig. 4B) and RT50 (24.6 6 1.7 vs. 31.1 6 1.8 ms), respectively (Fig. 4C) . Inversely, the muscles from the T4-treated mice demonstrated faster contraction and relaxation as we explained before [28] [29] [30] by significantly declining the TTP (39.1 6 0.7 ms) and the RT50 (18.9 6 0.8 ms) compared with those of the control (TTP; P , 0.01 and RT50; P , 0.05) and the memantine only group (TTP; P , 0.05 and RT50: P , 0.001) (Figs. 4B, C) . In addition, concomitant administration of memantine with T4 was not able to significantly change the T4-induced decrease in the TTP (38.4 6 1.1 ms) or the RT50 (19.3 6 0.8 ms). The TTP of memantine + T4 group was still significantly lower than those of the control (P , 0.001) and the memantine only group (P , 0.01), However, the RT50 of the memantine + T4 group was only significant compared with the memantine only (P , 0.001), but not the control group (P = 0.1558) (Figs. 4B, C) .
Fdev was also assessed within the murine in vivo physiological range (8-12 Hz) along with the baseline stimulation frequency of 4 Hz. Muscles from the T4-treated mice exhibited a significantly negative response to the increasing frequency at 10 Hz (vs. memantine; P , 0.05), 12 Hz (vs. control; P , 0.05), and 14 Hz (vs. control; P , 0.05) as indicated by ordinary 1-way ANOVA and there was no significant differences among the rest of the groups (Fig.  5A) . However, Friedman test of repeated measures ANOVA displayed a substantial influence for both the group (P , 0.001) and frequency (P , 0.001) variations on the Fdev. But, there was no considerable interaction between the 2 variants (Fig. 5A) . Notably, the force frequency response in this study is somewhat different from our previous reports, [28] [29] [30] where the control mice (7-9 months) typically show a considerable positive response compared with the negative response that we demonstrated here (9-12 months). The most likely explanation is that the mouse's age seems to be a key factor. We have illustrated that isolated papillary muscles from the older wild-type FVB/N mice RV (12-14 months) exhibited a slightly negative force frequency response, 33 in addition to a similar response that we have recently discovered in another group of mice (9-10 months). 34 The mice used in these studies are retired breeders and the exact age is not guaranteed. confirmed our preceding facts [28] [29] [30] and revealed that muscles from the T4-treated mice demonstrated a strikingly declined response versus those of the control (P , 0.01), but not the memantine only (P = 0.0769) group (Fig. 5B) . Memantine treatment could not prevent this dampened isoproterenol response in the muscles of the T4-treated mice and it continue to be considerably reduced compared with the muscles of control (P , 0.01) and memantine only-treated mice (P , 0.05) (Fig. 5B) . Besides, repeated measures ANOVA presented a notable effect for the group (P , 0.001) and the isoproterenol concentration (P , 0.001) variations on the Fdev, along with a substantial interaction between the 2 variants (P , 0.001) (Fig. 5B) . Finally, at maximal b-adrenergic stimulation, muscles of the T4 and the memantine + T4 groups exhibited arrhythmia in undoubtedly higher number of muscles (8/13 and 8/11, respectively) compared with those of the control (3/13) and the memantine alone (2/12) (Fig. 5C ).
DISCUSSION
Thyroid hormones affect the glutamatergic neurotransmission pathway in the central nervous system, where they have been anticipated as a key modulator of NMDA-R subunit expression in the hippocampus. 35 In addition, Losi et al 36 reported that thyroid hormones nongenomically regulate the activity of the NMDA-R and repressed the neuronal death driven by glutamate. Moreover, it has been shown that hypothyroidism could protect from cerebral ischemia because of subsequent decrease in glutamate release. 37 However, the relation between this glutamatergic pathway and thyroid hormone in the peripheral tissue, in particular the cardiovascular system, has never been exposed. Previous studies reported that NMDA-Rs are widely expressed in the hearts of human and rodent. 38, 39 The NMDA-R expression has been also detected in the vasculature, including the aorta and pulmonary artery. 39 In the vein of thyroid hormone, NMDA-R activation has been linked to some kind of circulatory diseases, such as heart failure, cardiac arrhythmias, and hypertension. [6] [7] [8] [9] [10] Therefore, it is rational to assume that the NMDA-R could be a prospective intervention target for the T4-induced cardiovascular changes, and we believe that this is the first study to examine this hypothesis.
Memantine is a noncompetitive NMDA-R antagonist 40 characterized by a fast-binding/dissociating activity, which allows for a fast course of action and less effect on physiologic functions compared with the other NMDA-R antagonists. 41, 42 Hence, memantine has been stated to offer much promise in the treatment of neurodegenerative disorder 43 and is presently used in moderate to severe Alzheimer's disease (AD) patient therapy in the United States and Europe. 42, 44 Memantine has been also shown to be a noncompetitive antagonist of both the serotonin (5-HT3) receptors 45 and the nicotinic cholinergic receptors, 46 and a dopaminergic receptor agonist. 47 Yet, when used in combination therapy, for example, its 5-HT3 antagonism could prevent the acetyl cholinesterase inhibitor gastrointestinal side effects. 42 Memantine is a well-tolerated drug, 42 so far little is known about its cardiovascular effects. 48 Clinical trials have shown that hypertension is one of the memantine side effects occurred in .2% of the patients at a larger rate compared with the placebo-treated patients, but it did not reach significance. 42 In the current study, we showed that memantine has no significant effect on the mouse BP. In agreement with our results, memantine at a similar dose (32 mg/kg) did not significantly affect the rat BP as well 49 and similarly the AP-5, an NMDA-R antagonist resulted in a very slight change in the BP of the sham rat. 7 In addition, a number of compromised cardiac upshots have been reported after memantine therapy. For instance, an increase in the deadly and nondeadly myocardial infarction in the users of memantine has been reported in a comparison of the users and nonusers of memantine in 2 large population databases. Though, this might be partly because of the sicker individual selection for memantine treatment. 48, 50 Also, concomitant administration of memantine with donepezil in patient with AD was displayed to increase the ECG PR interval. 51 Besides, memantine has been conveyed to exacerbate the ECG-corrected QT interval in the patients with AD. 52, 53 However, these patients have been diagnosed with severe heart diseases, in addition to old age and diabetes, which are known risk factors for the prolonged corrected QT interval. 52 Conversely, prolonged corrected QT interval was not recorded in the French PharmacoVigilance Database report regarding the patients receiving memantine therapy, and a small number of adverse cardiovascular effects, above all, cardiac bradycardia was documented. 54 Compatibly, the (+)-MK801, a noncompetitive NMDA receptor antagonist, was demonstrated to prompt bradycardia and positive inotropy in isolated rat cardiac tissues (right atria, left atria, and RV strips). 3 Overall, it has been suggested that memantine cardiovascular properties seem to be complicated, pretty indistinct, and require further experimental and clinical studies. 54 Here, we showed that memantine could not induce any considerable alteration in the cardiac structure and function as evidenced by the typical HW, in vivo echocardiographic LV structure/function, ECG parameters (HR, PR, QT, and QRS), and ex vivo RV contractile performance after memantine treatment in comparison with the control mice. Merely, memantine prolonged the relaxation time (RT50) of the contractile RV muscles; however, it did not reach significance (P = 0.1994; Kruskal-Wallis test). These valuable endings have been observed in the mice treated not only with the memantine alone, but also in combination with the T4 treatment, which resulted in numerous cardiac variations that were sufficient to increase the risk of cardiac mortality, even so, it did not befall. These data openly direct the cardiovascular safety and tolerability of memantine therapy. Yet, extra research is necessary to endorse these prospective advantageous outcomes.
On the other side, memantine has shown some cardiac therapeutic effects. D'Amico et al 55 conveyed that NMDA/ non-NMDA ionotropic excitatory amino acid antagonists, including memantine, are effective in preventing the reperfusion-induced, but not the ischemia-induced cardiac arrhythmia and mortality in rats. In addition, it has been reported that memantine could prevent the reduction in the rat LV cardiomyocyte nuclear size induced by cold stress, which has been suggested to either initiate or increase the rodent cardiovascular dysfunction, 56, 57 concluding that memantine might be a promising cardioprotective medication. 56 Actually, NMDA-R has been shown to play a key role in the induction of several heart failure/decreased cardiac contractility related pathways, such as the sympathoexcitation, 6,7 oxidative stress, 1,11 cardiomyocyte apoptosis, 1 myocardial fibrosis, 8 and stimulation of myocyte mitochondrial matrix metalloproteinase. 12 Even though T4-induced cardiac remodeling has been referred to similar mechanisms, including the sympathetic nervous system, 20 oxidative stress, 21, 22 cardiomyocyte apoptosis, 23 myocardial fibrosis, 24 and matrix metalloproteinase, 25, 26 memantine could not inhibit any of the T4-induced cardiac pathological manifestations in the current study. The inability of memantine to prevent these T4-prompted cardiac pathologies cannot be precisely rationalized. Increased NMDA-R1 upregulation within the paraventricular nucleus of the hypothalamus has been proposed to participate in the upraised sympathoexcitation during heart failure. Taking into consideration the valuable effects of b-blockers, a full understanding of sympathoexcitation could assist in uncovering novel treatments for the sympathetic dysfunction in failing hearts. 7 In this regard, propranolol, a b-adrenergic blocker, was displayed to significantly decrease the HW/BW ratio in the hyperthyroid hearts, indicating that T4-induced cardiac hypertrophy is linked to sympathetic nervous system. 20 Nonetheless, other studies conveyed that adrenergic stimulation is not involved in the T4-evoked cardiac hypertrophy in cats 58 and propranolol could not adjust the cardiomyocyte hypertrophy degree in hyperthyroid rats. 59 Hu et al 20 suggested that the T4-driven cardiac hypertrophy is complicated, and the multifaceted interactions between the sympathetic nervous system and the thyroid hormone's direct effect at the cellular level still need to be completely illustrated. 20 Similarly, NMDA-R activation has been reported to stimulate oxidative stress and apoptosis in cultured neonatal rat cardiomyocytes, signifying that it may play a key role in myocardial pathogenesis. 1 However, the source of reactive oxygen species, which resulted in these cardiac changes was not determined, 1 especially because we have previously shown the differential involvement of various sources of reactive oxygen species in the T4-induced hemodynamic changes and contractile dysfunction of the heart. 29 In addition, the scavenger of reactive oxygen species, N-acetylcystein, has been demonstrated to inhibit the NMDA-R-induced oxidative stress and cardiomyocyte apoptosis. 1 However, N-acetylcystein was only able to partially improve the thyroid hormone-induced shortening in ventricular action potential duration and could not attenuate the cardiac hypertrophy of the hyperthyroid rats. 60 Moreover, chronic activation of the NMDA-R was reported to increase the susceptibility to ventricular arrhythmias, which may be coupled with myocardial fibrosis. 8 Despite the absence of any ECG changes after T4 treatment in our model, Zhang et al 61 have established that hyperthyroidism increases the vulnerability to atrial fibrillation in rats without any increase in interstitial fibrosis, proposing that only longstanding hyperthyroidism (10 months) could result in myocardial fibrosis and cardiac dysfunction as described before. 24 Furthermore, agonizing the NMDA-R was shown 6Indicates a significant change compared with both the T4 and the (memantine + T4) groups. tIndicates a significant change compared with the (memantine + T4) group. , indicates a significant change compared with both the group and frequency variation (Friedman nonparametric repeated measures ANOVA followed by Dunn's post hoc multiple comparison test) or the group and the isoproterenol concentration variations (repeated measures ANOVA followed by Tukey-Kramer's post hoc multiple comparison test). Error bars of the 2 upper groups: control ( ) and memantine (I). Significance marks are directly above the error bar of the statistically significant group.
to activate the mitochondrial matrix metalloproteinase-9 leading to a reduction in the cardiomyocyte contractility and prolongation in both TTP and RT 11, 12, 50 in contrast to the sustained developed force and reduced TTP and RT in the RV muscles of our model. Even though hyperthyroid-induced hypertrophied hearts were associated with activated matrix metalloproteinase-1 and -2, 25, 26 clinical studies revealed the absence of substantial change in metalloproteinase-2 and -9 concentrations before and after thyrotoxicosis treatment, indicating that matrix metalloproteinases are doubtful to play a part in cardiovascular mortality linked to thyrotoxicosis. 62 Generally, considering discrepancies between our results and preceding studies, it is obvious that recognizing the mechanism(s) involved in the T4-induced cardiac hypertrophy and cardiac dysfunction is challenging and requires further investigation as previously reported. 20 Prominently, molecular, 7 immunocytochemical, 63 and biochemical 64 records have displayed that the NMDA-R expression could be adapted by alterations in the systemic BP. NMDA-R has been reported to markedly contribute to the hypertension prompted by raised sympathoexcitation associated with the left coronary ligationinduced heart failure in rats, 7 angiotensin II, 65 and carotid clamping in the rostral ventrolateral medulla of anesthetized rats. 66 In consistency with these outcomes, memantine, an NMDA-R blocker, significantly reduced the T4-induced hypertension in our model. Interestingly, a recent study revealed that the glutamatergic neurotransmission in the rostral ventrolateral medulla of conscious rats depends on the nitric oxide (NO)-NMDA-R pathway excitatory effects to control the systemic BP. 10 Indeed, we 29 and others 19 have shown that the NO synthase (NOS) pathway is a key player in the T4-evoked hypertension. Generally, the activation of the NOS has been reported in the hyperdynamic circulation after hyperthyroidism. Although endothelial NOS (eNOS) and inducible NOS (iNOS) could have a homeostatic role, neuronal NOS (nNOS) was projected as the crucial factor in the hyperthyroidism-induced hypertension in rats. [17] [18] [19] Notably, the nNOS activation with the subsequent NO production has been reported as a strategic NMDA-R signaling transducer 67 and has been involved in the regulation of BP and neurogenic hypertension as well. 68 Based on these findings, we strongly believe that the inhibitory effects of memantine on the NO-NMDA-R excitatory pathway could potentially be the main mechanism resulted in the significant prevention of the T4-induced hypertension in this study; however, this is currently under investigation.
CONCLUSIONS
Overall, our results openly direct the cardiovascular safety and tolerability of memantine therapy. Yet, extra research is necessary to endorse these prospective advantageous outcomes. Also, we believe that this is the first study to inspect the possible role of NMDA-R in the T4-stimulated circulatory disorders. Finally, our data show for the first time that NMDA-R could play a key role in the T4-induced hypertension, but not cardiac remodeling.
